These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 18667019)

  • 21. SPCG-4: a needed START to PIVOTal data to promote and protect evidence-based prostate cancer care.
    Wilt TJ
    J Natl Cancer Inst; 2008 Aug; 100(16):1123-5. PubMed ID: 18695131
    [No Abstract]   [Full Text] [Related]  

  • 22. Adjuvant radiotherapy after radical prostatectomy shows no ability to improve rates of overall and cancer-specific survival in a matched case-control study.
    Porter CR; Capitanio U; Perrotte P; Walz J; Isbarn H; Kodama K; Gibbons RP; Correa R; Karakiewicz PI
    BJU Int; 2009 Mar; 103(5):597-602. PubMed ID: 19021603
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Do we need the final results of the ERSPC trial?
    Albers P
    Eur Urol; 2007 Feb; 51(2):291-2. PubMed ID: 16949198
    [No Abstract]   [Full Text] [Related]  

  • 24. Prevention of nonvertebral fractures with oral vitamin D and dose dependency: a meta-analysis of randomized controlled trials.
    Bischoff-Ferrari HA; Willett WC; Wong JB; Stuck AE; Staehelin HB; Orav EJ; Thoma A; Kiel DP; Henschkowski J
    Arch Intern Med; 2009 Mar; 169(6):551-61. PubMed ID: 19307517
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Interest of the radiotherapy-hormonotherapy association in the treatment of the high-risk prostate cancer].
    Bolla M; Fourneret P; Descotes JL
    Bull Cancer; 2008 Dec; 95(12):1213-8. PubMed ID: 19091656
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vitamin D and cancer: more questions than answers remain.
    Lally RM
    ONS Connect; 2008 Sep; 23(9):23. PubMed ID: 18807712
    [No Abstract]   [Full Text] [Related]  

  • 27. Intermittent androgen deprivation therapy: conventional wisdom versus evidence.
    Tombal B
    Eur Urol; 2009 Jun; 55(6):1278-80. PubMed ID: 19303201
    [No Abstract]   [Full Text] [Related]  

  • 28. Twenty years of controversy surrounding combined androgen blockade for advanced prostate cancer.
    Moul JW
    Cancer; 2009 Aug; 115(15):3376-8. PubMed ID: 19484788
    [No Abstract]   [Full Text] [Related]  

  • 29. Estimates of clinically useful measures in competing risks survival analysis.
    Ambrogi F; Biganzoli E; Boracchi P
    Stat Med; 2008 Dec; 27(30):6407-25. PubMed ID: 18937229
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rural residence and prostate cancer screening with prostate-specific antigen.
    Stamatiou K; Skolarikos A
    Rural Remote Health; 2009; 9(2):1227. PubMed ID: 19594290
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Radiotherapy for high-risk patients after radical prostatectomy for prostate cancer: immediate postoperative or salvage?].
    Pasquier D; Kouto H; Ballereau C
    Prog Urol; 2009 Jul; 19(7):447-56. PubMed ID: 19559374
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Controversy over prostate-specific antigen screening has shifted from mortality to overtreatment issues.
    Ito K
    Int J Urol; 2009 Sep; 16(9):711-12. PubMed ID: 19777638
    [No Abstract]   [Full Text] [Related]  

  • 33. Can diet affect prostate cancer?
    Meyer JP; Gillatt DA
    BJU Int; 2002 Feb; 89(3):250-4. PubMed ID: 11856105
    [No Abstract]   [Full Text] [Related]  

  • 34. Vitamin supplements and cancer prevention: where do randomized controlled trials stand?
    Albanes D
    J Natl Cancer Inst; 2009 Jan; 101(1):2-4. PubMed ID: 19116387
    [No Abstract]   [Full Text] [Related]  

  • 35. [Vitamin D deficiency increases the risk of death from prostate cancer].
    Favrbo K
    Ugeskr Laeger; 2009 Apr; 171(15):1303. PubMed ID: 19425196
    [No Abstract]   [Full Text] [Related]  

  • 36. Re: Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial.
    Schröder FH; Roobol MJ
    BJU Int; 2009 Jan; 103(2):143-4. PubMed ID: 19076150
    [No Abstract]   [Full Text] [Related]  

  • 37. Pretreatment prostate-specific antigen velocity and the risk of death from prostate cancer in the individual with low-risk prostate cancer.
    D'Amico AV; Chen MH
    J Clin Oncol; 2009 Aug; 27(22):3575-6. PubMed ID: 19506151
    [No Abstract]   [Full Text] [Related]  

  • 38. Access to prostate cancer care and implications for survival among minorities.
    Oliver MN
    J Urol; 2009 Feb; 181(2):447-8. PubMed ID: 19095248
    [No Abstract]   [Full Text] [Related]  

  • 39. Social inequality and incidence of and survival from male genital cancer in a population-based study in Denmark, 1994-2003.
    Marså K; Johnsen NF; Bidstrup PE; Johannesen-Henry CT; Friis S
    Eur J Cancer; 2008 Sep; 44(14):2018-29. PubMed ID: 18667299
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [High-dosage brachytherapy of prostate cancer--a technique of the future].
    Kharchenko VP; Kaprin AD; Pan'shin GA; Khmelevskiĭ EV; Milenin KN; Egorova EV; Al'bitskiĭ IA
    Vopr Onkol; 2008; 54(6):765-7. PubMed ID: 19241856
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.